Akt and Bcl-xL Promote Growth Factor-independent Survival through Distinct Effects on Mitochondrial Physiology*

David R. PlasDagger§, Sunit TalapatraDagger, Aimee L. Edinger, Jeffrey C. Rathmell§, and Craig B. Thompson||

From the Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6160

Received for publication, November 21, 2000, and in revised form, December 20, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A comparison of Akt- and Bcl-xL-dependent cell survival was undertaken using interleukin-3-dependent FL5.12 cells. Expression of constitutively active Akt allows cells to survive for prolonged periods following growth factor withdrawal. This survival correlates with the expression level of activated Akt and is comparable in magnitude to the protection provided by the anti-apoptotic gene Bcl-xL. Although both genes prevent cell death, Akt-protected cells can be distinguished from Bcl-xL-protected cells on the basis of increased glucose transporter expression, glycolytic activity, mitochondrial potential, and cell size. In addition, Akt-expressing cells require high levels of extracellular nutrients to support cell survival. In contrast, Bcl-xL-expressing cells deprived of interleukin-3 survive in a more vegetative state, in which the cells are smaller, have lower mitochondrial potential, reduced glycolytic activity, and are less dependent on extracellular nutrients. Thus, Akt and Bcl-xL suppress mitochondrion-initiated apoptosis by distinct mechanisms. Akt-mediated survival is dependent on promoting glycolysis and maintaining a physiologic mitochondrial potential. In contrast, Bcl-xL maintains mitochondrial integrity in the face of a reduced mitochondrial membrane potential, which develops as a result of the low glycolytic rate in growth factor-deprived cells.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

There is increasing evidence that tissue homeostasis in multicellular organisms is controlled by the availability of growth factors (1). Within a given tissue, high levels of relevant growth factors promote increased cellular mass, metabolism, and proliferation. In contrast, when the availability of growth factor becomes limiting, cellular atrophy and an increased rate of apoptosis are observed. Many growth factors affect cellular responses through receptor-mediated recruitment and activation of the phosphoinositide 3-kinase (PI3K)1 and the serine/threonine kinase Akt (2, 3). Once activated, Akt can phosphorylate substrates involved in controlling a variety of cellular processes, including cellular metabolism and survival (4). The PI3K/Akt pathway is an important regulator of cellular homeostasis in vivo, as activating mutations of this pathway are correlated with multiple types of cancer. Akt itself was first identified as a viral oncogene, and deficiency in PTEN, an inositol phosphatase that opposes the activity of PI3K, is frequently found in numerous types of advanced cancers (5-7).

Akt activation by growth factor receptors prevents apoptosis by blocking the release of cytochrome c (8). A number of molecular targets for the inhibition of apoptosis by Akt have been proposed. Akt phosphorylates and inactivates pro-apoptotic proteins, including Bad and Forkhead family transcription factors (9, 10). In addition, Akt has been reported to stimulate the expression of anti-apoptotic Bcl-2 proteins, such as Bcl-xL and Mcl-1, through the activation of NF-kappa B (11, 12). However, it is not clear if these targets entirely account for the effects of Akt on cell survival.

Members of the Bcl-2 family are attractive Akt targets, as they have been shown to be potent regulators of apoptosis following growth factor withdrawal. Transgenic overexpression of anti-apoptotic family members prevents the induction of programmed cell death and leads to an accumulation of cells, whereas transgenic overexpression of pro-apoptotic family members can result in decreased cell numbers within an organ (13, 14). Anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, are localized to the outer mitochondrial membrane and function to maintain mitochondrial homeostasis upon growth factor withdrawal. Bcl-xL and Bcl-2 have been reported to promote mitochondrial homeostasis by promoting continued transport of metabolites across the outer membrane, despite decreases in cellular metabolism (15, 16). In the absence of growth factor, Bcl-xL facilitates cell survival by preserving cellular ATP production following the decrease in glycolysis that accompanies growth factor withdrawal.

Since both Akt and Bcl-xL can regulate cell survival and cellular metabolism, we have compared the bioenergetic properties of growth factor-deprived FL5.12 cells expressing either Akt or Bcl-xL. FL5.12 cells are nontransformed pro-B cells that depend on IL-3 for survival and proliferation. The results demonstrate that cells expressing Akt or Bcl-xL maintain distinct metabolic states in the absence of growth factor. Akt expression sustains sufficient glucose uptake and glycolysis to maintain a physiologic mitochondrial membrane potential in growth factor withdrawn cells. In contrast, Bcl-xL promotes the survival of growth factor-deprived cells by maintaining mitochondrial integrity and function, despite a decrease in mitochondrial potential that results from a decline in glucose-derived substrates. These differences in cellular metabolism suggest that there are fundamental differences in the mechanisms by which Akt and Bcl-xL promote cell survival.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- FL5.12 cells were cultured as described previously (17). Myristoylated Akt (mAkt) gene expression was induced for 18 h with 1 µg/ml of doxycycline (Sigma) treatment. Cell volume measurements were made using a Coulter Z2 instrument (Beckman Coulter). Where indicated, wortmannin (Calbiochem) and LY294002 (Sigma) were added to cultures at final concentrations of 100 nM and 10 µM, respectively. Glucose- and glutamine-free medium was made using the RPMI 1640 Select Amine Kit (Life Technologies, Inc.) and 10% dialyzed fetal bovine serum (Life Technologies, Inc.). Glucose and glutamine were supplemented to final concentrations as indicated.

Plasmid Constructs and Retroviral Transductions-- pUHD172-1Neo expressing rtTA was generously provided by J. Leiden, Abbott. Akt constructs were generously provided by N. Hay, University of Illinois, Chicago. mAkt was hemagglutinin (HA)-tagged at the C terminus, and both mAkt-HA and K179M Akt were cloned into pRevTRE (pRT, CLONTECH). Bcl-xL was ligated into pBabeMN-IRESGFP (Bcl-xL1, generously provided by G. Nolan, Stanford University) or pRT (Bcl-xL2). Retroviral expression vectors were virally transduced using the Phoenix packaging cell line (generously provided by G. Nolan) as described previously (18). Briefly, target cells were combined with the retrovirus and 4 µg/ml hexadimethrine bromide (Sigma), spun at 2500 rpm for 1.5 h, and selected with 3 mg/ml hygromycin (CLONTECH). Cell populations were cloned by limiting dilution. Three independently isolated clones expressing the epitope-tagged mAkt in an inducible manner (mAkt1, mAkt2, and mAkt3) were obtained and subjected to further study.

Protein Expression-- Lysates from cell lines were standardized for protein content and separated by SDS-polyacrylamide gel electrophoresis (Invitrogen). Blots were probed with either rabbit anti-Bcl-xL (13.6) (19), rabbit anti-Akt (New England Biolabs), or mouse anti-tubulin (Santa Cruz Biotechnology) and visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech).

Northern Blot-- Total RNA was prepared using TRIZOL (Life Technologies, Inc.) from cells cultured with or without IL-3 for 14 h. 10 µg of RNA were separated on a 1% formaldehyde agarose gel and probed with rat Glut1 cDNA (generously provided by M. Birnbaum, University of Pennsylvania). Loading was assessed by visualizing gels stained with ethidium bromide.

Flow Cytometry-- Cell viability assays were performed using propidium iodide as described (17). For mitochondrial potential determination, live cells were enriched by centrifugation over Ficoll, rested for 1 h, and incubated for 30 min at 37 °C with 200 nM tetramethylrhodamine ethyl ester (Molecular Probes). Analysis was performed in a FacsCalibur flow cytometer (Becton Dickinson).

Glycolysis and ATP Assays-- After 6 days without IL-3, 1 × 106 Ficoll-enriched live cells were resuspended in pre-warmed CO2-buffered Krebs solution (115 mM NaCl, 2 mM KCl, 25 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, 0.25% bovine serum albumin, pH 7.4) lacking glucose for 30 min at 37 °C. Cells were then washed and resuspended in 500 µl of Krebs buffer containing 10 mM glucose supplemented with 20 µCi/ml [5-3H]glucose (PerkinElmer Life Sciences) for 1 h at 37 °C, and the reaction was stopped by adding equal volume 0.2 N HCl. 3H2O was separated from [3H]glucose by evaporative diffusion of 3H2O in a closed chamber, as described (20). Total ATP levels were determined from 1 × 106 live cells, enriched by Ficoll, using the ATP bioluminescence assay kit HS II (Roche Molecular Biochemicals) (15).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Akt is involved in transmitting intracellular signals from growth factor receptors (21). We sought to determine whether Akt is involved in IL-3-dependent signal transduction in FL5.12 cells. FL5.12 cells were deprived of growth factor for 12 h, and recombinant IL-3 was reconstituted for the indicated time intervals. Addition of IL-3 resulted in rapid and transient phosphorylation of Akt, which was maximal 15 min after IL-3 addition (Fig. 1A). Activation of Akt was dependent on PI3K, since the PI3K inhibitors wortmannin or LY294002 prevented the induction of Akt phosphorylation (Fig. 1A and data not shown). Thus, Akt is a component of the proximal signal transduction machinery of the IL-3 receptor.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   The PI3K/Akt pathway transmits a growth signal from the IL-3 receptor. A, FL5.12-Bcl-xL cells were withdrawn from IL-3 for 18 h. IL-3 was reconstituted in the absence (NO TX) or the presence (WORT) of wortmannin, as indicated. Phosphorylated and total Akt levels were assessed in immunoblots (top and bottom panels, respectively). Lysates from cells expressing constitutively active myristoylated Akt were loaded as a positive control (mAkt). B, cellular volume was determined in cells that had been withdrawn from IL-3 (open diamonds) or in cells in which IL-3 had been reconstituted in the absence (closed diamonds) or the presence (closed squares) of LY294002 (LY). Cell volume is plotted as the percentage of initial cellular volume of cells growing in IL-3.

When FL5.12 cells are withdrawn from growth factor, they undergo progressive atrophy until they initiate programmed cell death. Bcl-xL protects from cell death in response to growth factor withdrawal, but it does not prevent cellular atrophy (22). Since the PI3K/Akt pathway is an important regulator of cell size in Drosophila (23), we investigated whether the PI3K/Akt pathway is required for cell growth following IL-3 readdition. Reconstitution of IL-3 in cultures that had been withdrawn from growth factor resulted in rapid recovery of cell size (Fig. 1B). Addition of the PI3K inhibitor LY294002 simultaneously with IL-3 resulted in a delay in the recovery of cell size, indicating that the PI3K pathway regulated cell growth in response to stimulation with IL-3. These data indicate that the PI3K/Akt pathway is important in transmitting cell growth signals in mammalian cells, as has been observed in Drosophila cells (23, 24).

In addition to promoting cell growth, the PI3K/Akt pathway also transmits cell survival signals from growth factor receptors (2, 25). To assess the role of Akt in promoting cell survival in FL5.12 cells, we established cell lines expressing constitutively active, mAkt (26). Addition of the Src myristoylation sequence to the N terminus of Akt targets it to the plasma membrane, conferring constitutive activity to the kinase (27). FL5.12 cells were infected with a retrovirus encoding an epitope-tagged mAkt under the control of a tetracycline response element. Three independent clones were isolated which expressed doxycycline-induced mAkt at a level comparable to the level of total Akt expressed in parental FL5.12 cells (Fig. 2). In the absence of induction, all three clones expressed low levels of mAkt. Withdrawal of IL-3 from wild-type FL5.12 cells resulted in loss of viability within 48 h, as determined by the ability of cells to exclude propidium iodide (Fig. 2, A and B). All three mAkt clones maintained viability over 6 days, whereas cells expressing kinase-deficient Akt died with kinetics similar to wild-type cells (Fig. 2A). As has been shown previously, cells expressing high and low levels of Bcl-xL (Bcl-xL1 and 2, respectively) maintained viability in the absence of growth factor in a dose-dependent manner (28). After 6 days of growth factor withdrawal, the remaining viable cells could be recovered quantitatively from mAkt- and Bcl-xL-expressing populations as assayed by IL-3 readdition and cloning by limiting dilution (data not shown). Thus, increased viability over 6 days represented true cell survival over the entire time course. Constitutively active Akt promotes cell survival in a dose-dependent manner, as doxycycline addition increased mAkt expression and cell survival concomitantly (Fig. 2, B and C).



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Constitutively active Akt protects cells from programmed cell death following growth factor withdrawal. Epitope-tagged mAkt was expressed in FL5.12 cells under the control of a tetracycline-responsive promoter. Three independent mAkt clones were isolated by limiting dilution and subjected to further analysis. A, IL-3 was removed from FL5.12 cells, vector control cells, and cells expressing Bcl-xL, mAkt, or kinase-deficient Akt (Akt KD). Cell viability was determined by measuring propidium iodide exclusion in triplicate. B, viability in the absence of IL-3 was measured over time in vector control (Vec. Ctrl.), Bcl-xL, and mAkt cells in the presence and absence of doxycycline (Dox). C, control and mAkt-expressing cells were cultured in the absence and the presence of doxycycline as shown, and cell lysates were probed for Akt (top) or alpha -tubulin as a control for loading (bottom). Note the slower mAkt mobility due to the presence of the HA epitope tag.

Akt signal transduction has been implicated in the control of cell cycle progression by stimulating increased translation of cyclin D (29). To determine whether Akt-dependent survival following growth factor withdrawal involved continued cell proliferation, we assessed the rates of DNA synthesis in cells growing in IL-3 and in cells that had been withdrawn from IL-3. Incorporation of the nucleotide analog bromodeoxyuridine (BrdUrd) was similar for all clones growing in IL-3 (Fig. 3). Following growth factor withdrawal, cells expressing either mAkt or Bcl-xL lacked significant levels of DNA synthesis, while maintaining significant viability (Fig. 3). In contrast, vector control cells also lack the ability to incorporate BrdUrd, but this reflects the fact that all these cells have died as indicated by their sub-diploid DNA content and inability to exclude propidium iodide (Fig. 2 and data not shown). These data suggest that Akt-dependent survival in FL5.12 cells does not require cell cycle progression.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Akt promotes cell survival in the absence of cell proliferation. Cells were pulsed for 1 h with bromodeoxyuridine (BrdU) while growing in IL-3 (top) or after 6 days of IL-3 starvation (bottom). Cells were fixed and stained with anti-BrdUrd and propidium iodide. BrdUrd staining in cells that are 2 N or greater is plotted. All vector control (Vec. Ctrl.) cells contained a sub-diploid DNA content after 6 days in the absence of IL-3 and therefore were not plotted. The percentage of BrdUrd+ cells is indicated.

FL5.12 cells undergo progressive atrophy when deprived of growth factor (22). Since Akt transmits cell growth signals from the IL-3 receptor, expression of constitutively active Akt could prevent cellular atrophy upon growth factor withdrawal. Cell size was assessed in cells that had been withdrawn from IL-3 by measuring forward scatter of equal numbers of live cells in a flow cytometer. Cells expressing mAkt maintained a larger cell size in the absence of growth factor, compared with cells expressing Bcl-xL (Fig. 4). Cell size correlated with mAkt expression, as cells induced with doxycycline were larger than uninduced cells. Although cells expressing mAkt remained larger than Bcl-xL cells, they still atrophied after growth factor withdrawal (data not shown). This indicates that mAkt can transmit a cell growth signal in the absence of IL-3, but it does not completely substitute for the cell growth and proliferative signals transmitted from the IL-3 receptor. Thus, activated Akt both promotes cell survival and prevents cellular atrophy in the absence of growth factor.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Akt attenuates cellular atrophy in response to growth factor withdrawal. mAkt expression was induced with doxycycline (Dox) as indicated, and cells were withdrawn from IL-3 for 6 days. Forward scatter of equal numbers of live cells from each cell line was determined in a flow cytometer. The curves for both mAkt clones are compared with the same curve from Bcl-xL-expressing cells.

Cellular atrophy is correlated with decreases in cellular metabolism and macromolecular synthesis (30-32). Since Akt signaling attenuates cellular atrophy, the metabolic status of mAkt and Bcl-xL cells was compared in the absence of growth factor. Total cellular ATP levels were assessed in cells that had been withdrawn from IL-3. Cells expressing mAkt contained more ATP than cells expressing Bcl-xL (Fig. 5), suggesting that cells expressing mAkt remained metabolically more active than cells expressing Bcl-xL. Furthermore, the prevention of cellular atrophy by Akt is correlated with increased metabolism in FL5.12 cells.



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 5.   Increased ATP in cells expressing mAkt. Doxycycline-treated cells were withdrawn from IL-3 for 6 days, and cellular lysates were prepared from equal numbers of live cells. Total ATP in lysates was determined in triplicate using a luminescent ATP assay. The data for cells expressing mAkt is the average of three separate clones.

In insulin receptor signal transduction, Akt regulates several aspects of glucose uptake, metabolism, and storage (33-35). The elevated amounts of ATP in mAkt cells may be due in part to the ability of mAkt to maintain glucose metabolism in the absence of growth factor. Akt can increase glucose metabolism in response to insulin by inducing the expression of the glucose transporters in insulin-responsive cell types (35). In contrast to insulin-responsive tissues, which primarily express Glut4, the major glucose transporter in lymphocytes is Glut1.2 Analysis of Glut1 mRNA in cells growing in the presence of IL-3 revealed no difference in mRNA levels between vector control cells and cells expressing mAkt or Bcl-xL (Fig. 6A). Following IL-3 withdrawal, Glut1 mRNA was undetectable in vector control and Bcl-xL cells but was still detectable in cells expressing mAkt (Fig. 6A). In addition to promoting increased Glut1 expression, mAkt sustained an overall increase in glycolysis in the absence of IL-3 (Fig. 6B). Following growth factor withdrawal, cells expressing mAkt mediated significantly increased glycolytic rates compared with cells expressing Bcl-xL (Fig. 6B). However, constitutively active Akt did not completely substitute for growth factor receptor signaling, since the rates of glycolysis in Akt-protected cells were lower than in cells growing in IL-3.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Akt-expressing cells maintain greater Glut-1 expression and glycolytic rates compared with Bcl-xL-expressing cells. A, vector control, Bcl-xL, and mAkt cells were treated with doxycycline for 18 h and cultured in the presence or absence of IL-3. Equal amounts of total RNA were probed in a Glut1 Northern blot (top). As a control for gel loading, 28 S and 18 S rRNAs were visualized by staining with ethidium bromide (bottom). B, mAkt expression was induced with doxycycline, and IL-3 was withdrawn from cells for 6 days. Equal numbers of live cells were washed and incubated with [5-3H]glucose for 1 h. Triplicate samples were removed from the cultures, and the conversion of [3H]glucose to [3H]H2O was used to determine glycolytic rates. The glycolytic rate for cells expressing mAkt is the average of three clones.

Mitochondrial potential is indicative of mitochondrial activity, and perturbations in inner membrane potential following growth factor withdrawal have been associated with the commitment to cell death (15). Therefore, mitochondrial membrane potential was assessed using the potentiometric dye tetramethylrhodamine ethyl ester (TMRE). Following IL-3 withdrawal, mitochondrial membrane potential was significantly reduced in cells expressing Bcl-xL (Fig. 7A). In contrast, there was no reduction in the mitochondrial potential of cells expressing mAkt following IL-3 withdrawal. TMRE fluorescence was reflective of mitochondrial potentials in these cells, since addition of agents that collapse the mitochondrial potential resulted in a decrease in TMRE staining (Fig. 7B). Thus, the difference in staining with TMRE alone was due to the difference in mitochondrial potential in cells expressing mAkt or Bcl-xL. These data indicate that cells expressing mAkt contain sufficient electron transport substrates to maintain mitochondrial potential, despite the absence of growth factors.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Akt-expressing cells maintain their mitochondrial potential in the absence of IL-3. A, TMRE was added to Bcl-xL-expressing cells or to doxycycline-treated mAkt-expressing cells in the presence or absence of IL-3. TMRE fluorescence was determined in a flow cytometer following a 30-min incubation at 37 °C. B, cells cultured in the absence of IL-3 were treated as in A, except that carbonyl cyanide chlorophenylhydrazone (CCCP) and chloroquine were added simultaneously with TMRE where indicated. The data for TMRE alone are identical to the data shown in A.

To survive growth factor withdrawal, cells must maintain cellular metabolism at a level sufficient to sustain viability. The data indicate that Akt-expressing cells are metabolically more active than Bcl-xL-expressing cells in the absence of growth factor, as determined by total cellular ATP, glycolytic rates, and mitochondrial potentials. One difference between Akt and Bcl-xL is the ability of Akt to regulate glucose metabolism. Glucose and glutamine are the major carbon sources for lymphocytes in culture medium (36, 37), and limiting concentrations of these nutrients resulted in decreased cellular glycolysis (data not shown). To determine whether the increased rate of glycolysis was necessary for Akt-dependent survival, we tested cell survival under conditions of nutrient limitation. As the concentrations of glucose and glutamine were decreased in the culture medium, a progressive impairment in the ability of mAkt to promote growth factor-independent survival was evident (Fig. 8). In contrast, Bcl-xL cells were unaffected by decreasing concentrations of carbon sources. Cells expressing mAkt also decreased in cell size prior to undergoing apoptosis as nutrients became more limiting (data not shown). These data suggest that Bcl-xL promotes cell survival by regulating a cell intrinsic effect on bioenergetics, rather than by regulating glucose uptake or utilization. In contrast, Akt is reliant on the availability of exogenous nutrients to promote cell survival.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 8.   Akt-dependent survival requires extrinsic energy sources. Cells were withdrawn from IL-3 as described in Fig. 2, except that cells were resuspended in medium containing reduced amounts of glucose and glutamine, as indicated. The expression of Bcl-xL in the two clones presented is shown in the bottom panel.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The data indicate that Akt can function to promote both cell growth and cell survival downstream of growth factor receptors. Akt is rapidly phosphorylated following stimulation with IL-3, identifying the kinase as a component of the proximal IL-3 receptor signaling pathway. Inhibition of the PI3K/Akt pathway prevents the rapid induction of cell growth upon re-stimulation of FL5.12 cells with IL-3. Constitutively active Akt both promotes cell survival and attenuates cellular atrophy in the absence of growth factor. Thus, Akt regulates both cell survival and cell size in mammalian cells.

Increases in Akt activity have been shown to result in increases in cyclin D expression, which results in cell cycle progression (29). However, constitutively active Akt does not support IL-3-independent proliferation in FL5.12 cells. Cells expressing Akt are slower to exit the cell cycle than cells expressing Bcl-xL following growth factor withdrawal (data not shown). Nonetheless, cells expressing constitutively active Akt do exit from the cell cycle while maintaining cellular viability. This indicates that mAkt is not sufficient to transform FL5.12 cells and that cellular proliferation is not necessary for Akt-dependent cell survival.

The dual role of Akt in controlling both cell growth and cell survival has been suggested by genetic studies of Akt in Drosophila. Ablation of Akt in embryos results in increases in apoptosis throughout the embryo (38). Overexpression of Akt in eye and wing imaginal discs results in increases in cell size, without increases in cell number (23). Importantly, overexpression of Akt does not increase cellular proliferation and does not overcome cell cycle arrest in the zone of nonproliferating cells in the wing imaginal disc (23). This indicates that Akt can promote increases in cell size without altering cell proliferation in Drosophila, in agreement with the findings in FL5.12 cells.

How can Akt simultaneously control both cell growth and cell survival? The answer may be linked to the control of cellular metabolism. Cellular growth requires the uptake and utilization of energy-rich metabolites. Similarly, to survive growth factor withdrawal, cells must establish a mechanism to sustain their metabolism. It is possible that Akt influences both cell growth and cell survival by sustaining increased cellular bioenergetics. In the absence of growth factor, constitutively active Akt promotes increases in cellular ATP levels, glycolytic rates, and mitochondrial potential, indicating that Akt mediates a global increase in cellular metabolism. This global increase may attenuate the alterations in cellular metabolism that are associated with growth factor withdrawal-induced programmed cell death.

Akt can control cellular metabolism on a number of levels. Here we report that IL-3 signal transduction is required to maintain Glut1 expression in FL5.12 cells. However, Akt activation is sufficient to induce Glut1 expression in these cells, even in the absence of IL-3. In addition to stimulating glucose uptake, Akt also controls glucose utilization within cells. Constitutively active Akt is sufficient to increase the overall rate of glycolysis in cells surviving growth factor withdrawal. Akt may increase glucose utilization by phosphorylating GSK-3beta or PFK-2 (33, 34). The finding that GSK-3beta overexpression results in apoptosis lends support to the possibility that Akt control of glucose metabolism contributes to its ability to promote cell survival (39).

The ability of Akt to maintain the glycolytic rate of a cell is sufficient to explain how Akt overexpression maintains the mitochondrial membrane potential. A higher glycolytic rate will result in greater substrate availability for mitochondrial electron transport. Consistent with this hypothesis, the ability of Akt to maintain the mitochondrial potential was found to be dependent on glucose. In contrast, Bcl-2 family proteins have been reported to maintain mitochondrial integrity following growth factor withdrawal by facilitating mitochondrial exchange of metabolites and ATP/ADP (15). This allows mitochondria to sustain coupled respiration in the face of a fall in membrane potential that occurs as a result of the decrease in glycolytic substrates.

Biochemical analysis of cells surviving growth factor withdrawal in an Akt-dependent manner indicates that these cells are metabolically more active than their Bcl-xL counterparts. To sustain high levels of metabolism and prevent atrophy, cells expressing Akt are reliant on external sources of energy. Akt cannot promote cell survival in the context of insufficient external energy sources. In contrast, cells that express Bcl-xL can maintain viability even in the context of limited external nutrient sources. Since Akt is a component of growth factor receptor signal transduction, constitutively active Akt may promote survival by transmitting partial cell growth signals that sustain cellular metabolism, whereas Bcl-xL promotes survival by allowing cells to adapt to a reduced metabolic state.

The data suggest that Akt does not promote cell survival solely by inactivating pro-apoptotic factors. If Akt functioned exclusively as an anti-apoptotic protein, cells surviving growth factor withdrawal would adopt a low energy phenotype, as do cells expressing Bcl-xL. The difference in the metabolic requirements of cells surviving due to Akt or Bcl-xL indicates cellular contexts in which each gene might be functional. Bcl-xL can mediate survival under limiting concentrations of nutrients. Thus, newly transformed cells that have not yet established an effective blood supply would be better served by expressing Bcl-xL than by expressing Akt. Vascularized tumors, in contrast, can survive the absence of specific growth factors by expressing Akt. These cells would maintain greater levels of metabolism, which might contribute to their oncogenic potential. The requirement for a rich source of nutrients may partially explain why mutations in PTEN, which result in elevations in Akt activity, are correlated with late stage, aggressive tumors (6, 7). In contrast, overexpression of Bcl-2 proteins correlates with low grade tumors with low mitotic indices (40).


    ACKNOWLEDGEMENTS

We thank N. Hay (University of Illinois, Chicago) for Akt constructs and F. Matschinsky (University of Pennsylvania) for help with the glycolysis assay. In addition, we thank members of the Thompson laboratory for technical help and reviewing the manuscript, especially Matthew Vander Heiden.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Both authors contributed equally to this work.

§ Supported by grants from the Irvington Institute for Immunological Research.

Supported by the Helen Hay Whitney Foundation.

|| To whom correspondence should be addressed: Dept. of Cancer Biology, University of Pennsylvania, 421 Curie Blvd., Philadelphia, PA 19104-6160. Tel.: 215-746-5514; Fax: 215-746-5511; E-mail: drt@mail. med.upenn.edu.

Published, JBC Papers in Press, January 12, 2001, DOI 10.1074/jbc.M010551200

2 J. C. Rathmell, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: PI3K, phosphoinositide 3-kinase; mAkt, myristoylated Akt; TMRE, tetramethylrhodamine ethyl ester; HA, hemagglutinin; IL, interleukin; BrdUrd, bromodeoxyuridine.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Raff, M. C. (1992) Nature 356, 397-400[CrossRef][Medline] [Order article via Infotrieve]
2. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]
3. Yao, R., and Cooper, G. M. (1995) Science 267, 2003-2006[Medline] [Order article via Infotrieve]
4. Kandel, E. S., and Hay, N. (1999) Exp. Cell Res. 253, 210-229[CrossRef][Medline] [Order article via Infotrieve]
5. Bellacosa, A., Testa, J. R., Staal, S. P., and Tsichlis, P. N. (1991) Science 254, 274-277[Medline] [Order article via Infotrieve]
6. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V. (1997) Nat. Genet. 15, 356-362[Medline] [Order article via Infotrieve]
7. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. (1997) Science 275, 1943-1947[Abstract/Free Full Text]
8. Kennedy, S. G., Kandel, E. S., Cross, T. K., and Hay, N. (1999) Mol. Cell. Biol. 19, 5800-5810[Abstract/Free Full Text]
9. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[Medline] [Order article via Infotrieve]
10. Kops, G. J., and Burgering, B. M. (1999) J. Mol. Med. 77, 656-665[CrossRef][Medline] [Order article via Infotrieve]
11. Jones, R. G., Parsons, M., Bonnard, M., Chan, V. S., Yeh, W. C., Woodgett, J. R., and Ohashi, P. S. (2000) J. Exp. Med. 191, 1721-1734[Abstract/Free Full Text]
12. Zong, W. X., Edelstein, L. C., Chen, C., Bash, J., and Gelinas, C. (1999) Genes Dev. 13, 382-387[Abstract/Free Full Text]
13. Chao, D. T., Linette, G. P., Boise, L. H., White, L. S., Thompson, C. B., and Korsmeyer, S. J. (1995) J. Exp. Med. 182, 821-828[Abstract]
14. Grillot, D. A., Merino, R., Pena, J. C., Fanslow, W. C., Finkelman, F. D., Thompson, C. B., and Nunez, G. (1996) J. Exp. Med. 183, 381-391[Abstract]
15. Vander Heiden, M. G., Chandel, N. S., Schumacker, P. T., and Thompson, C. B. (1999) Mol. Cell 3, 159-167[Medline] [Order article via Infotrieve]
16. Vander Heiden, M. G., Chandel, N. S., Li, X. X., Schumacker, P. T., Colombini, M., and Thompson, C. B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4666-4671[Abstract/Free Full Text]
17. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., and Thompson, C. B. (1997) Cell 91, 627-637[CrossRef][Medline] [Order article via Infotrieve]
18. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8392-8396[Abstract/Free Full Text]
19. Chang, B. S., Kelekar, A., Harris, M. H., Harlan, J. E., Fesik, S. W., and Thompson, C. B. (1999) Mol. Cell. Biol. 19, 6673-6681[Abstract/Free Full Text]
20. Ashcroft, S. J., Weerasinghe, L. C., Bassett, J. M., and Randle, P. J. (1972) Biochem. J. 126, 525-532[Medline] [Order article via Infotrieve]
21. Conlon, I., and Raff, M. (1999) Cell 96, 235-244[Medline] [Order article via Infotrieve]
22. Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A., and Thompson, C. B. (2000) Mol. Cell 6, 683-692[Medline] [Order article via Infotrieve]
23. Verdu, J., Buratovich, M. A., Wilder, E. L., and Birnbaum, M. J. (1999) Nat. Cell Biol. 1, 500-506[CrossRef][Medline] [Order article via Infotrieve]
24. Weinkove, D., Neufeld, T. P., Twardzik, T., Waterfield, M. D., and Leevers, S. J. (1999) Curr. Biol. 9, 1019-1029[CrossRef][Medline] [Order article via Infotrieve]
25. Kulik, G., Klippel, A., and Weber, M. J. (1997) Mol. Cell. Biol. 17, 1595-1606[Abstract]
26. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., and Hay, N. (1997) Genes Dev. 11, 701-713[Abstract]
27. Kohn, A. D., Takeuchi, F., and Roth, R. A. (1996) J. Biol. Chem. 271, 21920-21926[Abstract/Free Full Text]
28. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. (1993) Cell 74, 597-608[Medline] [Order article via Infotrieve]
29. Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., and Rosen, N. (1998) J. Biol. Chem. 273, 29864-29872[Abstract/Free Full Text]
30. Franklin, J. L., and Johnson, E. M. (1998) J. Cell Biol. 142, 1313-1324[Abstract/Free Full Text]
31. Deshmukh, M., Vasilakos, J., Deckwerth, T. L., Lampe, P. A., Shivers, B. D., and Johnson, E. M., Jr. (1996) J. Cell Biol. 135, 1341-1354[Abstract]
32. Deckwerth, T. L., and Johnson, E. M., Jr. (1993) J. Cell Biol. 123, 1207-1222[Abstract]
33. Deprez, J., Vertommen, D., Alessi, D. R., Hue, L., and Rider, M. H. (1997) J. Biol. Chem. 272, 17269-17275[Abstract/Free Full Text]
34. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
35. Barthel, A., Okino, S. T., Liao, J., Nakatani, K., Li, J., Whitlock, J. P., Jr., and Roth, R. A. (1999) J. Biol. Chem. 274, 20281-20286[Abstract/Free Full Text]
36. Brand, K., Leibold, W., Luppa, P., Schoerner, C., and Schulz, A. (1986) Immunobiology 173, 23-34[Medline] [Order article via Infotrieve]
37. Brand, K., Fekl, W., von Hintzenstern, J., Langer, K., Luppa, P., and Schoerner, C. (1989) Metabolism 38, 29-33[Medline] [Order article via Infotrieve]
38. Staveley, B. E., Ruel, L., Jin, J., Stambolic, V., Mastronardi, F. G., Heitzler, P., Woodgett, J. R., and Manoukian, A. S. (1998) Curr. Biol. 8, 599-602[Medline] [Order article via Infotrieve]
39. Pap, M., and Cooper, G. M. (1998) J. Biol. Chem. 273, 19929-19932[Abstract/Free Full Text]
40. Zhang, G. J., Kimijima, I., Abe, R., Watanabe, T., Kanno, M., Hara, K., and Tsuchiya, A. (1998) Anticancer Res. 18, 1989-1998[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.